184 related articles for article (PubMed ID: 33650297)
1. GW117: A novel serotonin (5-HT
Gao N; Zheng W; Murezati T; Gu W; Li X; Jin Z
CNS Neurosci Ther; 2021 Jun; 27(6):702-713. PubMed ID: 33650297
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of GW117 antidepressant action: melatonin receptor-mediated regulation of sleep rhythm.
Yang YQ; Tiliwaerde M; Gao NN; Zhang TT; Ji HX; Gu W; Jin ZL
Eur J Pharmacol; 2024 Feb; 964():176299. PubMed ID: 38160931
[TBL] [Abstract][Full Text] [Related]
3. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
Guardiola-Lemaitre B; De Bodinat C; Delagrange P; Millan MJ; Munoz C; Mocaër E
Br J Pharmacol; 2014 Aug; 171(15):3604-19. PubMed ID: 24724693
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.
Fuchs E; Simon M; Schmelting B
Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S17-20. PubMed ID: 16436935
[TBL] [Abstract][Full Text] [Related]
5. Agomelatine, a melatonin agonist with antidepressant properties.
Dubovsky SL; Warren C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist.
Ettaoussi M; Sabaouni A; Pérès B; Landagaray E; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
ChemMedChem; 2013 Nov; 8(11):1830-45. PubMed ID: 24031039
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant potential of Uncaria rhynchophylla and its active flavanol, catechin, targeting melatonin receptors.
Geng CA; Yang TH; Huang XY; Ma YB; Zhang XM; Chen JJ
J Ethnopharmacol; 2019 Mar; 232():39-46. PubMed ID: 30543912
[TBL] [Abstract][Full Text] [Related]
8. [Agomelatine: the first "melatoninergic" antidepressant].
Bánki MC
Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
[TBL] [Abstract][Full Text] [Related]
9. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.
Dekeyne A; Mannoury la Cour C; Gobert A; Brocco M; Lejeune F; Serres F; Sharp T; Daszuta A; Soumier A; Papp M; Rivet JM; Flik G; Cremers TI; Muller O; Lavielle G; Millan MJ
Psychopharmacology (Berl); 2008 Sep; 199(4):549-68. PubMed ID: 18523738
[TBL] [Abstract][Full Text] [Related]
10. The antidepressant-like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptors.
Sumaya IC; Masana MI; Dubocovich ML
J Pineal Res; 2005 Sep; 39(2):170-7. PubMed ID: 16098095
[TBL] [Abstract][Full Text] [Related]
11. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
12. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
Millan MJ; Brocco M; Gobert A; Dekeyne A
Psychopharmacology (Berl); 2005 Feb; 177(4):448-58. PubMed ID: 15289999
[TBL] [Abstract][Full Text] [Related]
13. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
Bourin M; Prica C
Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
[TBL] [Abstract][Full Text] [Related]
14. Neuropharmacological and antidepressant-like effects of ZY-1408: A novel serotonin/norepinephrine reuptake inhibitor and serotonin receptor 2C antagonist.
Gao N; Tiliwaerde M; Zheng W; Xiong J; Li X; Jin Z
Neuropharmacology; 2021 Jan; 182():108376. PubMed ID: 33122031
[TBL] [Abstract][Full Text] [Related]
15. Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.
Vengeliene V; Noori HR; Spanagel R
Neuropsychopharmacology; 2015 Dec; 40(13):2897-906. PubMed ID: 25994077
[TBL] [Abstract][Full Text] [Related]
16. Synergistic mechanisms involved in the antidepressant effects of agomelatine.
Tardito D; Molteni R; Popoli M; Racagni G
Eur Neuropsychopharmacol; 2012; 22 Suppl 3():S482-6. PubMed ID: 22867907
[TBL] [Abstract][Full Text] [Related]
17. Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam.
Bhutada P; Dixit P; Thakur K; Deshmukh P; Kaulaskar S
Kaohsiung J Med Sci; 2013 Jul; 29(7):362-7. PubMed ID: 23768699
[TBL] [Abstract][Full Text] [Related]
18. The mechanism, efficacy, and tolerability profile of agomelatine.
MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats.
Loiseau F; Le Bihan C; Hamon M; Thiébot MH
Psychopharmacology (Berl); 2005 Oct; 182(1):24-32. PubMed ID: 15986188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
